Search for stocks /

Dharmaj Crop Guard Ltd Q3 FY26: ₹1,895 Million Revenue, PAT Crashes 34% YoY, EPS Annualised at ₹10.28 – Is Agrochem Cycle Biting?


1. At a Glance – Pesticides, Profits & Pressure

₹809 crore market cap. ₹239 stock price. P/E of 16.8. Book value ₹131. ROCE 12%. ROE 9.28%. Debt-to-equity 0.31.

And then comes Q3 FY26…

Revenue: ₹1,895 million.
EBITDA: ₹73 million.
PAT: ₹8 million.

Quarterly profit down 34.8% YoY. OPM shrinks to 3.86%. EPS this quarter? ₹0.23. Annualised? ₹10.28.

Meanwhile, 3-year sales CAGR is 35%, but 3-year profit growth is just 7%. Debtor days have ballooned to 95.

So here’s the spicy question:

Is Dharmaj a growing agrochemical story temporarily stuck in a downcycle… or a margin story slowly getting sprayed by cost pressure?

Let’s open the pesticide bottle carefully.


2. Introduction – From Gujarat to Global Fields

Dharmaj Crop Guard was incorporated in 2015. That’s right — not even a decade old.

In Indian agrochemicals, that’s basically a teenager trying to sit at the adult table with giants like UPL and PI Industries.

Yet in under 10 years, it has built:

  • 190+ product portfolio
  • Presence in 24 states
  • 5,000+ dealers
  • 15,000+ retail touchpoints
  • Exports to 29 countries

Impressive? Yes.
Consistent margins? Not exactly.

This is a classic agrochemical formulation + active ingredient player. It manufactures pesticides, herbicides, fungicides, micro-fertilizers and plant growth regulators.

Translation:

If a farmer wants to kill something (insects, weeds, fungus), Dharmaj probably has a chemical for it.

But here’s the catch.

Agrochemicals are cyclical. Global demand swings. Raw material prices fluctuate. Exports can suddenly slow. And working capital becomes a monster during bad seasons.

So when Q3 shows a PAT collapse… is this weather noise or structural weakness?

Let’s decode.


3. Business Model – WTF Do They Even Do?

Dharmaj operates in three segments:

  1. Branded Formulations (B2C) – Selling finished products to retailers & farmers
  2. Institutional Formulations (B2B) – Bulk supply to other companies
  3. Active Ingredients (B2B) – Manufacturing technical chemicals

Revenue mix FY24:

  • Domestic: 91%
  • Exports: 9%

Formulations dominate revenue. Active ingredients is where the real margin potential lies — but it requires capex and scale.

They have:

  • Dahej plant with 8,000 MT technical capacity
  • 25,500 MT formulation capacity (only 50% utilised in FY23)
  • Saykha active ingredient facility commissioned Jan 2024
  • Plan to produce ~200 MT per month in 2025 (30% utilisation)

So capacity exists. Utilisation? Not yet peak.

The company also:

  • Entered South India cluster
  • Added depots
  • Commercialised 8 new products at Saykha
  • Planning ₹330 million herbicide capex by Q2 FY27

Question for you:

Is Dharmaj building future capacity ahead of demand… or is it chasing growth too aggressively?


4. Financials Overview – Numbers Don’t Lie (But They Do Shout)

All figures in ₹ crore (as per quarterly standalone table).

MetricLatest Qtr (Dec 2025)YoY Qtr (Dec 2024)Prev Qtr (Sep 2025)YoY %QoQ %
Revenue189.54174.51347.268.61%-45.41%
EBITDA7.329.5031.80-22.95%-76.98%
PAT0.771.1817.35-34.75%-95.56%
EPS (₹)0.230.355.13-34.3%-95.5%

Annualised EPS = ₹0.23 × 4 = ₹0.92

But wait. That’s only if we use Q3 alone.

Q1 FY26 EPS: ₹9.64
Q2 FY26 EPS: ₹5.13
Q3 FY26 EPS: ₹0.23

Average = (9.64 + 5.13 + 0.23) / 3 = ₹4.99

Annualised EPS = ₹4.99 × 4 = ₹19.96

Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!